Tr-ACT2 / Sunstate Biosciences - LARVOL DELTA

Antibody-encapsulated actinomycin D for targeted cancer treatments. (ASCO 2026) - "Recently, Tr-based antibody drug conjugates (ADCs), trastuzumab emtansine and trastuzumab deruxtecan, have emerged as a new class of anti-HER2 therapies by combining targeted antibodies with cytotoxic agents via linkers... Our patented single protein encapsulation (SPE) platform, allowing encapsulation of small-molecule drugs by a single protein (albumins or globulins) without artificial nanoparticles and chemical modifications to drugs and proteins, has achieved great success in development of 2 drug products, SPEDOX-6 under clinical trial (NCT0764018) and SPESN38-8 (IND #: 164346) under IND-enabling study based on albumin, which have prompted us to utilize antibody, such as Tr, to encapsulate cytotoxic payload, like actinomycin D (ACT), forming antibody encapsulated drugs (AEDs)...In vivo anticancer efficacy of Tr-ACT2 at 1 mg/kg vs irinotecan at 50 mg/kg using A549 mouse model has been evaluated, showing that Tr-ACT2 was significantly more effective in suppressing..."

Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Antibody encapsulated drug: Tr-ACT2 for targeted treatments of various cancers (AACR 2026) - "Trastuzumab (Tr) has demonstrated efficacy in treatment of HER2+ breast cancer and advanced gastric cancer. Recently, Tr-based antibody drug conjugates (ADCs), Kadecyla and Enhertu, have emerged as a new class of anti-HER2 therapies by combining targeted antibodies with cytotoxic agents via linkers...Therefore, smarter and more efficient designs are urgently needed. Our patented single protein encapsulation (SPE) platform, allowing encapsulation of small-molecule drugs by a single protein (albumins or globulins) without artificial nanoparticles and chemical modifications to drugs and proteins, has achieved great success in development of 2 drug products, SPEDOX-6 under human clinical trial (NCT0764018) and SPESN38-8 (IND #: 164346) under IND-enabling study based on albumin, which have prompted us to utilize antibody, such as Tr to encapsulate cytotoxic payload, actinomycin D (ACT, RNA polymerase inhibitor), forming antibody encapsulated drugs (AEDs)... We have developed..."

Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor